Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review evaluates previous studies on androgen-progestin combinations for male contraception, concluding that long-acting injectable formulations appear promising due to their effectiveness and minimal short-term adverse effects.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

This study found that suppressing allopregnanolone production in late gestation fetal sheep altered CNS activity and behavioral responses to transient asphyxia, effects mitigated by an analog co-infusion.

This study found that in Withdrawal Seizure-Prone mice, ethanol withdrawal decreased the sensitivity of GABA A receptors to GABAergic neurosteroids in certain areas of the brain.

Birth control pills help treat acne, especially when caused by excess male hormones, and are safe to use with antibiotics.

This study provides a detailed overview of 1,295 clinical trials related to alcohol dependence registered on ClinicalTrials.gov, highlighting that 59.15% of these trials have been completed, primarily as interventional studies, with most located in North America.

This study of Black and Hispanic inner-city teens found that Norplant retention rates were 71% at one year and 62% at two years, with a history of induced abortion predicting higher continuation.

This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This abstract describes the Dermatologic Surgery journal's focus on providing comprehensive peer-reviewed content in dermatologic surgery but reports no new research findings.

This study examined 142 patients with subclinical thyroid disorders and found a high incidence of comorbidities like renal diseases. Researchers reported that good medication adherence was associated with better quality of life, indicating a significant relationship between adherence and quality of life.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after 6 months compared to those containing levonorgestrel.

In this study, sustained-release sodium valproate showed high efficacy in achieving seizure remission for adults with focal and generalized epilepsy over one year, but side effects like weight gain and tremor were more frequent among heterozygous carriers of certain gene variants.

This review discusses ethanol-based transethosome vesicles for drug delivery through the skin, but reports no new clinical results.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This study reports that subcutaneous testosterone pellets in peri- and postmenopausal women provided sustained hormone release and potential benefits for sexual function, but raised concerns about safety, variability, and dosing inconsistencies.

This study found that stilbamidine and hydroxystilbamidine can inhibit the release of specific enzymes from lysosomes and mitochondria in rabbit liver at certain concentrations, with effects similar to cortisol and chloroquine.

This review discusses the use of different types of oral contraceptive pills and highlights their effectiveness, potential side effects, and contraindications without presenting new clinical data.

NB-002 is a promising new topical treatment for fungal nail infections, showing better results than a non-medicated option.

In this study, a needle-free supersonic atomizer delivering Bacopa monnieri extract with hyaluronan was found to enhance hair growth in mice more effectively than the traditional smear method and minoxidil.

This research reports that oral contraceptives may cause melasma in 24-29% of users, with minimal improvement after stopping the drug and limited effectiveness of hydroquinone treatment.

This case report describes a 66-year-old male with benign prostatic hyperplasia who developed urinary incontinence after starting venlafaxine, which resolved upon discontinuation of the medication.

This study found that Yangxuebushen Decoction significantly promoted hair regrowth and improved hair follicle structure in a cyclophosphamide-induced alopecia mouse model by reducing inflammation, oxidative stress, and apoptosis.

This update provides information on new drug approvals but does not offer new clinical research findings.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This study found that using urine tenofovir monitoring for PrEP adherence is well-accepted and may help overcome adherence barriers among participants at a U.S. urban clinical center.

This study found that bupropion was associated with a higher risk of hair loss compared to other antidepressants, with paroxetine presenting the lowest risk.

This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.